These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 25315069

  • 1. δEF1 associates with DNMT1 and maintains DNA methylation of the E-cadherin promoter in breast cancer cells.
    Fukagawa A, Ishii H, Miyazawa K, Saitoh M.
    Cancer Med; 2015 Jan; 4(1):125-35. PubMed ID: 25315069
    [Abstract] [Full Text] [Related]

  • 2. Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta.
    Shirakihara T, Saitoh M, Miyazono K.
    Mol Biol Cell; 2007 Sep; 18(9):3533-44. PubMed ID: 17615296
    [Abstract] [Full Text] [Related]

  • 3. TGF-β drives epithelial-mesenchymal transition through δEF1-mediated downregulation of ESRP.
    Horiguchi K, Sakamoto K, Koinuma D, Semba K, Inoue A, Inoue S, Fujii H, Yamaguchi A, Miyazawa K, Miyazono K, Saitoh M.
    Oncogene; 2012 Jun 28; 31(26):3190-201. PubMed ID: 22037216
    [Abstract] [Full Text] [Related]

  • 4. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
    Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ.
    Nat Cell Biol; 2008 May 28; 10(5):593-601. PubMed ID: 18376396
    [Abstract] [Full Text] [Related]

  • 5. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells.
    Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, Berx G, Cano A, Beug H, Foisner R.
    Oncogene; 2005 Mar 31; 24(14):2375-85. PubMed ID: 15674322
    [Abstract] [Full Text] [Related]

  • 6. BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1.
    Du J, Yang S, An D, Hu F, Yuan W, Zhai C, Zhu T.
    Cell Res; 2009 Apr 31; 19(4):487-96. PubMed ID: 19308091
    [Abstract] [Full Text] [Related]

  • 7. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.
    Tryndyak VP, Beland FA, Pogribny IP.
    Int J Cancer; 2010 Jun 01; 126(11):2575-83. PubMed ID: 19839049
    [Abstract] [Full Text] [Related]

  • 8. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.
    Park SM, Gaur AB, Lengyel E, Peter ME.
    Genes Dev; 2008 Apr 01; 22(7):894-907. PubMed ID: 18381893
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer.
    Lee JY, Park MK, Park JH, Lee HJ, Shin DH, Kang Y, Lee CH, Kong G.
    Oncogene; 2014 Mar 06; 33(10):1325-35. PubMed ID: 23474752
    [Abstract] [Full Text] [Related]

  • 11. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer.
    Wu X, Zhu Z, Li W, Fu X, Su D, Fu L, Zhang Z, Luo A, Sun X, Fu L, Dong JT.
    Breast Cancer Res; 2012 May 08; 14(3):R73. PubMed ID: 22569290
    [Abstract] [Full Text] [Related]

  • 12. Ets1 and ESE1 reciprocally regulate expression of ZEB1/ZEB2, dependent on ERK1/2 activity, in breast cancer cells.
    Sinh ND, Endo K, Miyazawa K, Saitoh M.
    Cancer Sci; 2017 May 08; 108(5):952-960. PubMed ID: 28247944
    [Abstract] [Full Text] [Related]

  • 13. BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells.
    Yu JM, Sun W, Hua F, Xie J, Lin H, Zhou DD, Hu ZW.
    Cancer Lett; 2015 Sep 01; 365(2):190-200. PubMed ID: 26049022
    [Abstract] [Full Text] [Related]

  • 14. BMP-6 promotes E-cadherin expression through repressing deltaEF1 in breast cancer cells.
    Yang S, Du J, Wang Z, Yuan W, Qiao Y, Zhang M, Zhang J, Gao S, Yin J, Sun B, Zhu T.
    BMC Cancer; 2007 Nov 13; 7():211. PubMed ID: 17997862
    [Abstract] [Full Text] [Related]

  • 15. DNA methylation and not H3K4 trimethylation dictates the expression status of miR-152 gene which inhibits migration of breast cancer cells via DNMT1/CDH1 loop.
    Sengupta D, Deb M, Rath SK, Kar S, Parbin S, Pradhan N, Patra SK.
    Exp Cell Res; 2016 Aug 15; 346(2):176-87. PubMed ID: 27475839
    [Abstract] [Full Text] [Related]

  • 16. New mode of DNA binding of multi-zinc finger transcription factors: deltaEF1 family members bind with two hands to two target sites.
    Remacle JE, Kraft H, Lerchner W, Wuytens G, Collart C, Verschueren K, Smith JC, Huylebroeck D.
    EMBO J; 1999 Sep 15; 18(18):5073-84. PubMed ID: 10487759
    [Abstract] [Full Text] [Related]

  • 17. IL-8 suppresses E-cadherin expression in nasopharyngeal carcinoma cells by enhancing E-cadherin promoter DNA methylation.
    Zhang RL, Peng LX, Yang JP, Zheng LS, Xie P, Wang MY, Huang BJ, Zhao HR, Bao YX, Qian CN.
    Int J Oncol; 2016 Jan 15; 48(1):207-14. PubMed ID: 26530812
    [Abstract] [Full Text] [Related]

  • 18. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition.
    Beltran M, Puig I, Peña C, García JM, Alvarez AB, Peña R, Bonilla F, de Herreros AG.
    Genes Dev; 2008 Mar 15; 22(6):756-69. PubMed ID: 18347095
    [Abstract] [Full Text] [Related]

  • 19. ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.
    Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, Bondesson M, Quinlan P, Thompson A, Krishnamurthy S, Esteva FJ, Gustafsson JÅ.
    Breast Cancer Res; 2012 Nov 16; 14(6):R148. PubMed ID: 23158001
    [Abstract] [Full Text] [Related]

  • 20. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity.
    Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist P, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A.
    Oncogene; 2007 Oct 25; 26(49):6979-88. PubMed ID: 17486063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.